Thompson Emily F, Shum Kathryn, Wong Richard W C, Trevisan Giorgia, Senz Janine, Huvila Jutta, Leung Samuel, Huntsman David G, Gilks C Blake, McAlpine Jessica N, Hoang Lynn, Jamieson Amy
Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
Department of Pathology, United Christian Hospital, Hong Kong, Hong Kong.
Int J Gynecol Cancer. 2022 Oct 3;32(10):1229-1235. doi: 10.1136/ijgc-2022-003763.
Vulvar squamous cell carcinoma and in situ lesions can be stratified by human papillomavirus (HPV) and status into prognostic risk groups using p16 and p53 immunohistochemistry. We assessed the significance of vulvar squamous cell carcinoma resection margin positivity for either differentiated vulvar intra-epithelial neoplasia (dVIN) or abnormal p53 immunohistochemistry, and other pathologic variables, in a cohort of patients with HPV-independent (HPV-I) p53 abnormal (p53abn) vulvar squamous cell carcinomas.
Patients with stage I-II HPV-I p53abn vulvar squamous cell carcinoma with negative invasive margins who did not receive adjuvant radiation from a single institution were included. Tumors underwent margin reassessment using p53 immunohistochemistry. Cases were segregated into (1) morphologic dVIN at margin; or (2) abnormal p53 immunohistochemistry staining at margin without morphologic dVIN (p53abn immunohistochemistry); or (3) margins negative by morphology and p53 immunohistochemistry. Clinicopathologic/outcome data were collected.
A total of 51 patients were evaluated: (1) 12 with dVIN on margin; (2) 12 with p53abn immunohistochemistry on margin without morphologic dVIN; and (3) 27 with margins negative for morphologic dVIN and p53abn immunohistochemistry. The recurrence rate for patients with dVIN or p53abn immunohistochemistry on the margin was equally high at 75% each, compared with 33% with margins negative for morphologic dVIN and p53abn immunohistochemistry (p=0.009). On multivariate analysis, positive in situ margins maintained an association with disease recurrence (p=0.03) whereas invasive margin distance (radial and deep), lymphovascular invasion, and tumor size did not.
Patients with stage I-II HPV-I vulvar squamous cell carcinoma with margins positive for either dVIN or p53abn immunohistochemistry without morphologic dVIN showed increased disease recurrence, regardless of invasive margin distance. These findings show that p53 immunohistochemistry is a useful adjunct for evaluating margin status in HPV-I vulvar squamous cell carcinoma and may support repeat excision for positive in situ margins (dVIN or p53abn immunohistochemistry).
外阴鳞状细胞癌及原位病变可通过人乳头瘤病毒(HPV)状态,并利用p16和p53免疫组化分为不同的预后风险组。我们评估了在一组HPV非依赖性(HPV-I)、p53异常(p53abn)的外阴鳞状细胞癌患者中,外阴鳞状细胞癌切除边缘阳性对于分化型外阴上皮内瘤变(dVIN)或p53免疫组化异常以及其他病理变量的意义。
纳入来自单一机构的I-II期HPV-I、p53abn外阴鳞状细胞癌患者,其浸润边缘阴性且未接受辅助放疗。肿瘤通过p53免疫组化进行边缘重新评估。病例分为:(1)边缘存在形态学dVIN;或(2)边缘p53免疫组化染色异常但无形态学dVIN(p53abn免疫组化);或(3)形态学及p53免疫组化边缘均为阴性。收集临床病理/转归数据。
共评估51例患者:(1)12例边缘存在dVIN;(2)12例边缘p53abn免疫组化阳性但无形态学dVIN;(3)27例形态学dVIN及p53abn免疫组化边缘均为阴性。边缘存在dVIN或p53abn免疫组化阳性患者的复发率均同样高达75%,而形态学dVIN及p53abn免疫组化边缘阴性患者的复发率为33%(p=0.009)。多因素分析显示,原位边缘阳性与疾病复发相关(p=0.03),而浸润边缘距离(径向和深部)、脉管浸润及肿瘤大小则无相关性。
I-II期HPV-I外阴鳞状细胞癌患者,若边缘dVIN或p53abn免疫组化阳性但无形态学dVIN,无论浸润边缘距离如何,疾病复发风险均增加。这些结果表明,p53免疫组化是评估HPV-I外阴鳞状细胞癌边缘状态的有用辅助手段,对于原位边缘阳性(dVIN或p53abn免疫组化)可能支持再次切除。